What is ATYR's current stock price?

ATYR (aTyr Pharma, Inc.) is currently trading at $0.49 with a market cap of $48.0M.

What sector is aTyr Pharma, Inc. in?

aTyr Pharma, Inc. (ATYR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ATYR a good stock to buy?

Analysts have a Hold consensus on ATYR with a price target of $5.13. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ATYR aTyr Pharma, Inc.

Healthcare

$0.49-7.28%ClosedMarket Cap: $48.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.83

P/S

252.87

EV/EBITDA

-0.70

DCF Value

$-0.04

FCF Yield

-123.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

-11754.7%

Operating Margin

-38573.7%

Net Margin

-36857.4%

ROE

-99.9%

ROA

-87.9%

ROIC

-105.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-10.8M	$—
Q4 null	$0.00	$-14.0M	$—
FY null	$190.0K	$-74.1M	$—
Q3 null	$190.0K	$-25.7M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$5.13

Target (Median)

$1.25

Target Range

$1.00 - $17.00

2 Strong Buy2 Buy6 Hold0 Sell0 Strong Sell

Freedom BrokerBuy

2026-05-20

RBC CapitalSector Perform

2025-11-07

Wells FargoEqual Weight

2025-09-16

RBC CapitalSector Perform

2025-09-16

LUCID CAPITAL MARKETSNeutral

2025-09-15

Trading Activity

Insider Trades

View All

Zaknoen Saradirector

SellWed May 13

SCHIMMEL PAULdirector

SellWed May 13

Lucas Svetlanadirector

SellWed May 13

Gross Jane Adirector

SellWed May 13

Coughlin Timothydirector

SellWed May 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.66

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Peers

MGX